Meridian Bioscience, Inc. (NASDAQ:VIVO)

12/13

Stock near 52-wk low and just raised guidance for 2012.

Very solid looking company. Nice quick ratio and strong returns make it very appealing. Decent dividend, too. Not really sure of what sort of things they have in the pipeline, but their core business seems to be doing well. Very nice growth rates top it off.

Growth company that is also growing it's dividend. Also might be a takeover target in foreseeable future.

Good fundamentals...no LT debt, div paying stock.

No debt a lot of cash high yield won't go down as much over the next 2-3 months and will come back strong

h1n1 or some other virus will be back. long term buy.

There's always next season's pandemic to consider, long term buy

Always profitable, and by policy pays out most cash in dividends. Even with the high payout ratio, the stock price appreciation still beats the market, making the total return even better. Compound price and dividends for a $100 portfolio over the past 10 to 20 years to see what I mean.

Awesome management

msn screen:

5 year div. growth >= 20 %
annual eps growth >= 25%
debt/eq <= 0.5
current dividend >= 2.5%

Rapid testing products for medical conditions. Help keep malpractice rates down and is becoming cheaper. Get's the patient tested for certain illnesses quickly which means earlier treatment, which means cheaper for the medical company

Meridian Biosciences has been a great pick for me since 1989. It was one of the very first stocks I owned, and my second DRIP. It has very strong financials, an intelligent business plan, and many products in its pipeline. This is an excellent small-cap stock for getting in on the ground floor.

ibd

Well managed company whose products will only see more demand in coming years.

MERIDIAN IS POISED TO GAIN NEW BUSINESS UNFORTOLD

Vivo's services are always going to be necessary, the world is not exactly getting healthier and healthier. They presently have good numbers and have shown some growth in the past. I'm confident that this is one of those stocks to watch.

excellent financials. high percentage of insider ownership

Most robust point of care testing portfolio- growth not likely to slow much given the diverse lab tests available- life science sector should improve over time.